Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 4.52
(5.36%)
CNY 4.52
(5.36%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 222.19 Million CNY | 402.57% |
| 2022 | 44.21 Million CNY | 217.22% |
| 2021 | -37.71 Million CNY | 92.29% |
| 2020 | -489.47 Million CNY | -87.69% |
| 2019 | -260.79 Million CNY | 17.59% |
| 2018 | -316.44 Million CNY | -30.53% |
| 2017 | -242.43 Million CNY | -44.98% |
| 2016 | -167.21 Million CNY | -53.88% |
| 2015 | -108.66 Million CNY | -33.15% |
| 2014 | -81.6 Million CNY | 46.06% |
| 2013 | -151.29 Million CNY | -147.97% |
| 2012 | -61.01 Million CNY | -25.89% |
| 2011 | -48.46 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 142.47 Million CNY | -19.37% |
| 2024 Q1 | 198.24 Million CNY | -10.78% |
| 2024 Q2 | 166.93 Million CNY | -15.79% |
| 2023 Q4 | 222.19 Million CNY | 23.27% |
| 2023 FY | 222.19 Million CNY | 402.57% |
| 2023 Q3 | 180.24 Million CNY | -17.49% |
| 2023 Q1 | 173.33 Million CNY | 292.05% |
| 2023 Q2 | 218.45 Million CNY | 26.03% |
| 2022 Q4 | 44.21 Million CNY | 395.05% |
| 2022 Q2 | -78.91 Million CNY | -726.85% |
| 2022 FY | 44.21 Million CNY | 217.22% |
| 2022 Q3 | -14.98 Million CNY | 81.01% |
| 2022 Q1 | 12.58 Million CNY | 133.38% |
| 2021 Q1 | 27.61 Million CNY | 105.64% |
| 2021 Q3 | 139.41 Million CNY | -35.17% |
| 2021 FY | -37.71 Million CNY | 92.29% |
| 2021 Q4 | -37.71 Million CNY | -127.05% |
| 2021 Q2 | 215.03 Million CNY | 678.77% |
| 2020 FY | -489.47 Million CNY | -87.69% |
| 2020 Q1 | -186.88 Million CNY | 28.34% |
| 2020 Q2 | -357.39 Million CNY | -91.24% |
| 2020 Q3 | -373.29 Million CNY | -4.45% |
| 2020 Q4 | -489.47 Million CNY | -31.12% |
| 2019 FY | -260.79 Million CNY | 17.59% |
| 2019 Q3 | -101.98 Million CNY | 67.18% |
| 2019 Q4 | -260.79 Million CNY | -155.71% |
| 2019 Q2 | -310.77 Million CNY | -296.55% |
| 2019 Q1 | -78.36 Million CNY | 75.23% |
| 2018 Q1 | -265.37 Million CNY | 15.16% |
| 2018 FY | -316.44 Million CNY | -30.53% |
| 2018 Q4 | -316.44 Million CNY | -9.99% |
| 2018 Q3 | -287.69 Million CNY | -16.42% |
| 2018 Q2 | -247.12 Million CNY | 6.88% |
| 2017 Q2 | -190.13 Million CNY | 8.83% |
| 2017 FY | -242.43 Million CNY | -44.98% |
| 2017 Q1 | -208.55 Million CNY | 5.23% |
| 2017 Q4 | -312.81 Million CNY | -40.91% |
| 2017 Q3 | -222 Million CNY | -16.76% |
| 2016 Q2 | -130.86 Million CNY | 38.66% |
| 2016 Q4 | -220.05 Million CNY | 2.06% |
| 2016 Q3 | -224.68 Million CNY | -71.69% |
| 2016 Q1 | -213.33 Million CNY | -96.33% |
| 2016 FY | -167.21 Million CNY | -53.88% |
| 2015 Q4 | -108.66 Million CNY | -5.62% |
| 2015 FY | -108.66 Million CNY | -33.15% |
| 2015 Q3 | -102.88 Million CNY | 85.14% |
| 2015 Q2 | -692.18 Million CNY | -948.18% |
| 2015 Q1 | 81.6 Million CNY | 200.0% |
| 2014 Q4 | -81.6 Million CNY | 0.0% |
| 2014 Q1 | 171.29 Million CNY | 0.0% |
| 2014 FY | -81.6 Million CNY | 46.06% |
| 2013 FY | -151.29 Million CNY | -147.97% |
| 2012 FY | -61.01 Million CNY | -25.89% |
| 2011 FY | -48.46 Million CNY | 0.0% |